Anthera Pharmaceuticals, Inc. (ANTH) Initiates Expanded and Extended PEARL-SC Phase 2b Clinical Study in Lupus With A-623 - A Subcutaneous Dual Inhibitor of Membrane and Soluble B-Cell Activating Factor (BAFF or BLyS)
7/29/2010
More...
|
Astex Therapeutics Scientists Describe Novel HSP90 Inhibitors In Two Key Publications In Journal Of Medicinal Chemistry
7/29/2010
More...
|
ArQule, Inc. (ARQL) Announces Initiation by Kyowa Hakko Kirin of Phase 2 Clinical Trial in Asia with ARQ 197 in Gastric Cancer
7/28/2010
More...
|
Tibotec Pharmaceuticals Ltd Announces TMC278 Pivotal Phase 3 Clinical Trials Achieve Primary Objective
7/23/2010
More...
|
Neovacs SA Achieves Key Clinical Milestones in Trials for Lupus & Arthritis
7/21/2010
More...
|
Immunacia’s ViroStatics Reports Phase II Data on VS411, an AV-HALT for Treating HIV/AIDS, During the XVIII International AIDS Conference
7/19/2010
More...
|
Tobira Therapeutics Inc.'s Next-Generation Once-Daily CCR5/CCR2 Antagonist Demonstrates Potent CCR2 Inhibition, Antiviral Activity, Safety and Tolerability in Treatment-Experienced Patients With HIV
7/19/2010
More...
|
Immunacia's Genetic Immunity Reports Phase II Data on DermaVir, a Therapeutic Vaccine for HIV/AIDS, During the XVIII International AIDS Conference: A 70% Viral Load Reduction Demonstrated in HIV Drug-naive Individuals
7/19/2010
More...
|
Phase II Data from FIT Biotech’s HIV Immunotherapy Show Reduction in Viral Load and Increase in CD4 Cell Count
7/19/2010
More...
|
Pegylated Liposomal Doxorubicin Fails to Best Carboplatin-Paclitaxel in Ovarian Cancer, National Cancer Institute Phase II Study
7/16/2010
More...
|
Stentys Completes Enrollment In Clinical Study Of Its Breakthrough Stent To Treat Acute Myocardial Infarction
7/15/2010
More...
|
Noscira Presents Results of Phase IIa Clinical Trial with Nypta(R) (Tideglusib) on Alzheimer's Disease at International Conference on Alzheimer's Disease (ICAD)
7/15/2010
More...
|
Starpharma Holdings Ltd Receives FDA Clearance To Commence Phase 2 Bacterial Vaginosis Study For Vivagel(R)
7/15/2010
More...
|
BioInvent Interim Report
7/14/2010
More...
|
Stem Cell Transplantation Successfully Treats Therapy-Resistant Chronic Leukemia, Heidelberg University Hospital Study Finds
7/13/2010
More...
|
Immunacia's Genetic Immunity Presents DermaVir at the 7th International Conference on Nanosciences & Nanotechnologies – A Unique Nanomedicine for Therapeutic HIV Vaccine
7/12/2010
More...
|
Medivir AB (MVIRb.F) Announces Phase 2b 24-week Interim Results of TMC435 in Treatment-naive Patients Chronically Infected with Genotype-1 Hepatitis C Virus
7/12/2010
More...
|
BioInvent And ThromboGenics NV Announce Positive Results from Phase II VTE Prophylaxis Study; Shows TB-402 Superior Antithrombotic Activity Compared to Sanofi-Aventis (France) (SASY.PA) Enoxaparin
7/9/2010
More...
|
Genmab A/S (GEN.CO) Announces Interim Results of Ofatumumab Phase II Study in Multiple Sclerosis
7/6/2010
More...
|
Evotec AG (EVTG.F) Starts Phase II Clinical Studies in Treatment-Resistant Depression
7/1/2010
More...
|
Unblinded Phase IIa Clinical Trial Data Delivers Excellent Results for Novexatin(R), NovaBiotics Ltd Lead Product Candidate for the Treatment of Fungal Nail Infection
6/30/2010
More...
|
Forest Laboratories, Inc. (FRX), Gedeon Richter Ltd. Say Phase 2 Diabetic Pain Drug Test Ineffective
6/29/2010
More...
|
Astellas Pharma Inc. (YPH.BE) Announces Oral Presentation of SGLT2 Inhibitor Detailing Safety and Efficacy in Patients With Type 2 Diabetes at the American Diabetes Association Meeting
6/29/2010
More...
|
BioAlliance Pharma Presents Phase III Results with Loramyc(R) (Miconazole Lauriad(R)) and Ongoing Phase II Trial with Clonidine Lauriad(R)
6/28/2010
More...
|
GENFIT Corp. (ALGFT) Announces its Development Plan for GFT505
6/28/2010
More...
|
Pluristem Therapeutics is Advancing Toward Two Phase IIb Clinical Trials for Treatment of Critical Limb Ischemia and Moderate-Severe Claudication
6/28/2010
More...
|
Ipsen’s Partner Roche (RHHBY) Confirms The Promising Efficacy Profile Of Taspoglutide
6/28/2010
More...
|
t2cure GmbH’s Cellular Therapeutic Receives Orphan Drug Designation from FDA, European Medicines Evaluation Agency Recommendation for Buerger’s Disease
6/24/2010
More...
|
MediGene AG (MDGEF.PK) Reports Additional Phase II Results of EndoTAG(TM)-1 for the Treatment of Triple Receptor-Negative Breast Cancer; Clinical Trial Objective Achieved
6/24/2010
More...
|
Results From Randomized Study of Immunomedics, Inc. (IMMU)'s Epratuzumab in Patients With Systemic Lupus Erythematosus Presented at European Rheumatology Congress
6/21/2010
More...
|
Positive Phase 2 Data on RDEA594, Ardea Biosciences, Inc.'s Lead Product Candidate for the Treatment of Hyperuricemia and Gout, Presented at the Annual European Congress of Rheumatology
6/18/2010
More...
|
Innovacell Includes First Patients in a Phase IIb Study for Its Cell Therapy Product urocell(R) , for the Treatment of Stress Urinary Incontinence
6/18/2010
More...
|
OBI-1 Developed by Ipsen and Inspiration Biopharmaceuticals Has Obtained a Positive Opinion for the Orphan Drug Status in Europe
6/17/2010
More...
|
UCB SA And Immunomedics, Inc. (IMMU) Release: New Data From EMBLEM(TM) Study Show Pipeline Drug Epratuzumab Provided Significant Efficacy for Patients Suffering From Moderate to Severe Systemic Lupus Erythematosus
6/16/2010
More...
|
Bristol-Myers Squibb Company (BMY) Says Arthritis Drug Trial BMS-945429/ALD518 Met Goal
6/16/2010
More...
|
Bristol-Myers Squibb Company (BMY) Release: New Data for Investigational Antibody Blocking IL-6 in Rheumatoid Arthritis Patients to be Presented at Annual Congress of European League Against Rheumatism
6/16/2010
More...
|
Immunomedics, Inc. (IMMU) Says Lupus Drug, EMBLEM Shows Efficacy
6/16/2010
More...
|
Morria Biopharmaceuticals Plc Announces Positive Safety, Tolerability and Preliminary Efficacy Results for MRX-4 Phase II Study in Allergic Rhinitis at the EAACI Congress
6/15/2010
More...
|
Alexion Pharmaceuticals Inc. (ALXN) Release: Substantial Disease Burden of PNH Demonstrated in Data from International and Asian Patient Registries Presented at European Hematology Association
6/14/2010
More...
|
Antisoma PLC (ASM.L) Announces AS1413 And AS1411 Presentations At EHA
6/14/2010
More...
|
Revotar Biopharmaceuticals Starts Phase II Clinical Trial in COPD Patients with Inhaled Bimosiamose
6/10/2010
More...
|
Active Biotech AB's TASQ Prostate Cancer Project Presented At American Society of Clinical Oncology
6/7/2010
More...
|
Antisoma PLC (ASM.L) Announces Presentation At ASCO Of New Data Supporting AS1413 And AS1411
6/7/2010
More...
|
Action Pharma Obtains Encouraging Preliminary Results In A Phase II Clinical Trial With AP214
6/7/2010
More...
|
Can-Fite BioPharma Announces Opening of CF101 Dermatology IND with Phase 2/3 Psoriasis Protocol
6/7/2010
More...
|
Promising Safety, Tolerability and Efficacy Results from Morria Biopharmaceuticals Plc' MRX-4 Phase II Study in Allergic Rhinitis to be Presented at the upcoming EAACI Congress
6/3/2010
More...
|
Nabriva Therapeutics Initiates Phase II Of Pleuromutilin Antibiotic BC-3781
6/2/2010
More...
|
Celladon Corporation: Phase 2 Clinical Trial Data Show Significant Improvements in Outcomes and Symptoms in Advanced Heart Failure Patients Treated with Celladon's Genetically Targeted Enzyme Replacement Therapy MYDICAR(R)
6/1/2010
More...
|
Relevare Pharmaceuticals Ltd. Presents Latest Clinical Trial Data on CNSB015 at Third International Congress on Neuropathic Pain in Athens, Greece
5/28/2010
More...
|
PhotoCure Announces Results From Phase II Study In Acne With Visonac(TM)
5/28/2010
More...
|
Can-Fite BioPharma Receives Israeli MoH Approval to Conduct a Phase II Clinical Trial Evaluating the Efficacy of CF101 in Patients with Glaucoma
5/24/2010
More...
|
Report on Phase II Clinical Study of Marshall Edwards, Inc. (NVGN)'s Phenoxodiol in Prostate Cancer to Be Presented at American Society of Clinical Oncology
5/21/2010
More...
|
Vectura Group plc's NVA237 Phase II Data at the American Thoracic Society Meeting
5/21/2010
More...
|
Antigenics Inc. (Lexington, MA) (AGEN): Encouraging Data From University of California, San Francisco (UCSF) Phase I/II Study Presented on Oncophage(R) Vaccine at International Conference on Brain Tumor Research and Therapy
5/20/2010
More...
|
Guardian Technologies International, Inc. (GDTI.OB) to Begin Phase II Clinical Trials of Signature Mapping TBDx(TM) TB Diagnostics
5/19/2010
More...
|
NicOx SA (COX.PA) Provides Strategic Update; Company Decides to Delay Initiation of Phase 2 Study of NCX 6560; Seeks Alternative Funding Options
5/19/2010
More...
|
Vaxon Biotech SA Successfully Completes Its Phase I/II Trial Of Vx-001 Cancer Vaccine, Phase III Ready To Start In NSCLC
5/19/2010
More...
|
Immutep S.A. Announces Oral Presentation At American Society of Clinical Oncology Annual Meeting Of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
5/18/2010
More...
|
Revotar Biopharmaceuticals Presents Positive Results In Phase IIa Ozone Study With Bimosiamose For COPD
5/18/2010
More...
|
Neovacs SA Achieves Significant Milestones in Two Clinical Trials
5/17/2010
More...
|
Swedish Orphan Biovitrum AB Presents First Positive Kiobrina(R) Clinical Phase II Data
5/6/2010
More...
|
Swedish Orphan Biovitrum Presents First Positive Kiobrina(R) Clinical Phase II Data
5/6/2010
More...
|
MediGene AG (DX:MDG) Publishes First, Preliminary Results Obtained in a Phase II Clinical Trial of EndoTAGTM-1 for the Treatment of Triple Receptor-negative Breast Cancer
5/6/2010
More...
|
BioInvent And ThromboGenics NV Announce Positive Topline Results from Phase II VTE Prophylaxis Study with Anti-Factor VIII (TB-402)
5/6/2010
More...
|
TxCell Announces Positive Preliminary Results from the Phase I/IIa Clinical Trial of OvaSave(R) in Crohn's Disease
4/30/2010
More...
|
Tikcro Technologies Announced BioCancell Therapeutics Receives U.S. FDA Approval to Continue Phase IIb Superficial Bladder Cancer Clinical Trial and Interim Results
4/30/2010
More...
|
NovaBiotics Ltd's Novexatin(R) IND Filing Planned For Phase IIb Study And Completion Of Fundraising
4/30/2010
More...
|
Albireo Announces Positive Results From a Study With A3309 in Patients With Chronic Constipation
4/29/2010
More...
|
Second Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals's Universal Flu Vaccine
4/28/2010
More...
|
Verva Pharmaceuticals Announces Commencement of VVP808 Clinical Trial in Type 2 Diabetes
4/27/2010
More...
|
Proteo Inc. (PTEO.OB)/Proteo Biotech AG (PTEO.OB): Successful Completion of Patient Recruitment for the Phase II Clinical Trial on Elafin in Patients with Esophagus Cancer
4/23/2010
More...
|
AFFiRiS AG Alzheimer's Vaccine AD02 Already in Clinical Phase II
4/23/2010
More...
|
Morria Biopharmaceuticals Plc Announces Initiation of Its Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug
4/21/2010
More...
|
Octapharma AG Trial on Intravenous Immunoglobulin (IVIG) in Alzheimer's Disease at ICAD 2010 Congress
4/19/2010
More...
|
First Peripheral Vascular Disease Patient Treated With Ark Therapeutics' High Dose VEGF-D In Phase I/IIa Trial
4/19/2010
More...
|
OctoPlus' Licensee Biolex, Inc. Makes Third Presentation At EASL Confirming Locteron's Superior Product Profile
4/19/2010
More...
|
Ocera Therapeutics, Inc. Presents Data on the Prevalence of Mild Hepatic Encephalopathy Defined as Neurocognitive Impairment in Patients with Liver Cirrhosis at EASL Annual Meeting
4/16/2010
More...
|
OctoPlus: Improved Tolerability Profile of Locteron Confirmed by Data Presented at EASL Conference
4/16/2010
More...
|
Vertex Pharmaceuticals (MA) (VRTX): 59 Percent of Patients Overall Achieved SVR with Telaprevir-Based Regimens in Study 107 After Not Achieving SVR with at Least One Prior Course of Treatment for Hepatitis C Virus Infection
4/15/2010
More...
|
Medivation, Inc. (MDVN) and Astellas Pharma Inc. Announce Publication in The Lancet of Positive Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
4/15/2010
More...
|
Kenta Biotech Reports 100% Survival with Panobacumab in Life-Threatening Hospital-Acquired Pneumonia
4/15/2010
More...
|
OctoPlus' Locteron Data Presented at EASL Conference Show 65% Reduction in Flu-Like Side Effects With Comparable Efficacy in Hepatitis C
4/15/2010
More...
|
Report from Living Cell Technologies Ltd.'s Russian Phase I/IIa Diabetes Trial
4/7/2010
More...
|
Symphogen A/S Announces Initiation of Phase 1/2 Trial of Sym004 in Patients with Advanced Solid Tumors in the US
4/1/2010
More...
|
Can-Fite BioPharma Steps Forward to the 3rd and Last Stage of Its Phase I/II Liver Cancer Study with the CF102 Drug
4/1/2010
More...
|
BioDiem Ltd. (BDM.AX) Update on Pandemic Influenza Vaccine
3/31/2010
More...
|
ProSensa B.V. Initiates Clinical Development of PRO044 in an Open Label Phase I/II Study
3/30/2010
More...
|
Living Cell Technologies Ltd. Receives Approval to Progress Its Human Phase II Trial of DIABECELL(R) Treatment for Diabetes to Next Stage with Encouraging Data
3/30/2010
More...
|
Action Pharma Completes Dosing In Phase II Clinical Trial With AP214 To Prevent Acute Kidney Injury Associated With Cardiac Surgery
3/29/2010
More...
|
Oramed Pharmaceuticals Inc. (ORMP.OB) Announces Completion of Pivotal Phase 2b Clinical Trials of it's Oral Insulin Capsule, ORMD-0801 for Type 2 Diabetes
3/25/2010
More...
|
Diamyd Medical AB Granted Orphan Drug Designation in the US
3/23/2010
More...
|
Positive Data In GW Pharmaceuticals's Sativex(R) Phase IIb Trial
3/23/2010
More...
|
Antisoma PLC (ASM.L) Initiates Phase IIb Trial Of AS1411 In Acute Myeloid Leukaemia
3/18/2010
More...
|
Acucela Inc. and Otsuka Pharmaceutical Co., Ltd. Receive FDA Fast Track Designation for ACU-4429 in Patients with Dry AMD
3/17/2010
More...
|
Allon Therapeutics, Inc. Receives European Orphan Drug Status for Davunetide
3/17/2010
More...
|
PCI Biotech Reports Successful Completion of the Third Dose Group in the Phase I/II Amphinex(R) Trial
3/16/2010
More...
|
OctoPlus Announces Publication of Positive Locteron Interim Phase IIb Data
3/16/2010
More...
|
OctoPlus Announces Update On Publication Of Positive Locteron Interim Phase IIb Data
3/16/2010
More...
|
Initiation of Two Phase II Studies with Ipsen's Proprietary BIM 23A760 First-in-Class Chimeric Compound in the Treatment of Acromegaly and Carcinoid Syndrome Due to Neuroendocrine Tumors
3/15/2010
More...
|
ProFibrix Reports Phase II Results of Hemostasis Product Fibrocaps(TM) and Appoints New Chief Medical Officer
3/11/2010
More...
|
CBio Limited Secures Another Clinical Trial Milestone
3/11/2010
More...
|
The New England Journal of Medicine Publishes Clinical Results On Karo Bio AB's
3/11/2010
More...
|
Mologen AG (MOLGF.PK) Receives Approval For Clinical Study With Cancer Drug MGN1703
3/5/2010
More...
|
Agennix AG Announces Longer-Term Mortality Results From Talactoferrin Phase 2 Trial in Severe Sepsis
2/26/2010
More...
|
Amarillo Biosciences (AMAR) Announces Australian Phase 2 Oral Interferon Clinical Trial Indicates Benefit in Preventing Influenza-Like Illness in Older Participants
2/16/2010
More...
|
Circassia Limited Achieves Positive Phase II Clinical Results With Ragweed Allergy T-Cell Vaccine Results Mark Third Successful Phase II Study With ToleroMune(R) T-Cell Vaccines
2/12/2010
More...
|
OctoPlus Announces That Locteron Interim Phase IIb Data Have Been Accepted for Oral and Poster Presentations at International Liver Congress in April
2/10/2010
More...
|
ThromboGenics NV: Positive Microplasmin Phase II Data Published in Ophthalmology
2/9/2010
More...
|
Kamada Ltd. Announces Enrollment of First Patient in Its Pivotal Study for Inhaled AAT in Europe
2/8/2010
More...
|
Clinical Trial Delays Hit Lipoxen (LPX.L) Revenues
2/5/2010
More...
|
Hybrigenics Receives Positive Answers From European Medicines Evaluation Agency on Clinical Phase IIb Efficacy Study
2/3/2010
More...
|
Vantia Therapeutics' Lead Candidate VA106483 Enters Phase IIb Trial for Nocturia
2/2/2010
More...
|
Ark Therapeutics: First Refractory Angina Patient Treated with VEGF-D shortform (EG011) in Phase I/IIa Trial
2/2/2010
More...
|
Synosia Therapeutics Announces Positive Interim Results for Potential First-in-Class Treatment for Parkinson's Disease
2/1/2010
More...
|
Lipid Therapeutics Announces Start of Phase IIb Clinical Trial
1/29/2010
More...
|
BTG plc (BGC.L) Commences Phase IIa Study of Pleneva(TM) for Multiple Sclerosis
1/21/2010
More...
|
Oramed Pharmaceuticals Inc. (ORMP.OB) Announces Completion of Patient Enrollment for Pivotal Phase 2B Clinical Trials of ORMD-0801
1/19/2010
More...
|
Circassia Limited Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
1/19/2010
More...
|
MorphoSys AG Enrolls First Patient in Phase 1b/2a Clinical Trial for MOR103 Program in Rheumatoid Arthritis
1/19/2010
More...
|
AVIR Green Hills Biotechnology AG: Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine deltaFLU
1/13/2010
More...
|
Cytheris SA Initiates INSPIRE 2, a Phase II Clinical Trial of Recombinant Human Interleukin-7 (CYT107) in Chronically Infected HIV Patients Who Fail to Achieve Optimal Immune Reconstitution under HAART Therapy
1/12/2010
More...
|
Apogenix Initiates Clinical Phase II Study with its Lead Compound APG101 in Glioblastoma
1/11/2010
More...
|
Hybrigenics Receives Authorization To Dose Prostate Cancer Patients Twice Daily With Oral Inecalcitol
1/6/2010
More...
|
VBL Therapeutics Initiates Phase 2 Clinical Trial of VB-201 in Patients with Psoriasis
1/5/2010
More...
|
Immutep S.A. Announces Final Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer
1/4/2010
More...
|
NovaBiotics Ltd Successful Completion of Phase IIa Clinical Development of its Nail Fungus Treatment, Novexatin(R)
1/4/2010
More...
|
Flamel Technologies (FLML) Announces the Initiation of a Phase 2a Clinical Trial of Flamel's IFN-Alpha-2b XL in Patients with Chronic Hepatitis C Virus Infection
12/18/2009
More...
|
BioAlliance Pharma: Entry into Clinical Phase: Clonidine Lauriad(R) into Phase II and AMEP(TM) into Phase I
12/15/2009
More...
|
Can-Fite BioPharma to Initiate Phase II Clinical Trial with CF101 for the Treatment of Glaucoma
12/15/2009
More...
|
KeyNeurotek Pharmaceuticals Reports Breakthrough In The Treatment Of Patients With Severe Traumatic Brain Injury In A Phase IIa Study
12/14/2009
More...
|
Addex Pharmaceuticals (ADXN.SW) Stops Lead Drug Trial Due To Liver Problems
12/14/2009
More...
|
Primary Endpoint Reached In Active Biotech AB's TASQ Phase II Clinical Trial In Prostate Cancer Patients
12/14/2009
More...
|
Ariad Pharmaceuticals, Inc. (ARIA) Announces Updated Data from Clinical Trial of Its Investigational mTOR Inhibitor, Ridaforolimus, In Combination with Trastuzumab
12/14/2009
More...
|
Cosmo Pharmaceuticals S.p.A.'s CB-03-01 Phase II Pilot Study In Acne Demonstrates Superiority Over Retin A(R)
12/11/2009
More...
|
ThromboGenics NV Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD)
12/11/2009
More...
|
Knopp NeuroSciences Reports Presentation of Encouraging Clinical Trends in a Phase 2 Study of KNS-760704 in ALS
12/9/2009
More...
|
Oxagen Limited Announces Completion of Recruitment in Phase IIb Dose Range-Finding Clinical Trial in New Oral Treatment for Asthma
12/9/2009
More...
|
BioAlliance Pharma: Doxorubicin Transdrug(R): Significant Increased Survival Rate In Patients With Advanced Hepatocellular Carcinoma Treated In A Phase II Clinical Trial
12/8/2009
More...
|
Cytheris SA Announces Initiation of CONVERT, a Phase I/IIa Study of Recombinant Human Interleukin-7 (CYT107) in Combination with Antiviral Therapy and Vaccination for Treatment of Chronic Hepatitis B Virus
12/8/2009
More...
|
Neovacs SA Initiates a Phase II Clinical Trial of TNFa Kinoid in Rheumatoid Arthritis Patients Failing TNFa Monoclonal Antibody Therapy
12/8/2009
More...
|
Gentium S.p.A. Announces Final Clinical Trial Results for Defibrotide Presented at the American Society of Hematology Conference
12/8/2009
More...
|
Celgene International Sárl (CELG): Phase II Data Evaluating REVLIMID(R) + Rituximab in Relapsed Patients with Chronic Lymphocytic Leukaemia Presented at American Society of Hematology
12/7/2009
More...
|
Antisoma PLC (ASM.L)'s AS1413 Regimen Yields High Response Rate And Durable Responses In Patients With Secondary AML, A Poor-Risk Population Underserved By Current Treatment Options
12/7/2009
More...
|
Clavis Pharma ASA: Positive Phase II Clinical Data For Clavis Pharma's Elacytarabine Presented At American Society of Hematology Annual Meeting
12/7/2009
More...
|
Q-Med AB and Oceana Therapeutics Take Major Step Towards SOLESTA(TM) US Regulatory Filing
12/7/2009
More...
|
Successful Phase I/II Clinical Trial for BiondVax Pharmaceuticals' Universal Flu Vaccine
12/7/2009
More...
|
PharmaSurgics to Begin Phase II Clinical Trial for Prevention of Post-Surgical Adhesions
12/3/2009
More...
|
Lightlake Therapeutics Inc. Receives Ethical Approval to Begin Subject Selection for Future Phase II Clinical Trial for New Obesity Drug, in Helsinki, Finland
12/3/2009
More...
|
Optinose Announces Study Results Of Intranasal Device For Treating Chronic Rhinosinusitis With Nasal Polyps
12/2/2009
More...
|
Dermagen Inc. Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
12/2/2009
More...
|
Agennix AG Announces Positive Results With Talactoferrin in Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Severe Sepsis
12/1/2009
More...
|
Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) ATIR(TM) for Reduction of Transplant Related Mortality Following an Allogeneic Stem Cell Transplantation Using a Mismatched Donor
11/30/2009
More...
|
Biovitrum AB's Kiobrina(TM) Shows Positive Phase II Results In Preterm Infants
11/25/2009
More...
|
Ipsen Initiates an Advanced Endometrial Cancer Program with BN83495, its First-in-Class Steroid Sulfatase (STS) Inhibitor
11/25/2009
More...
|
Cytheris SA Announces Initiation of National Cancer Institute/National Institutes of Health (NIH) Sponsored Phase I/IIa Clinical Study of Tumor Vaccination and Interleukin-7 (IL-7) in Patients with High Risk Pediatric Solid Tumors
11/23/2009
More...
|
GENFIT Corp. (ALGFT): Extremely Promising Gft505 Results In Phase II
11/23/2009
More...
|
Moberg Derma Reports Positive Phase II Results For K201 Against Atopic Eczema
11/20/2009
More...
|
Medivir AB (MVIRb.F): Epiphany Biosciences, Inc. Announces Positive Results from Its Phase 2b Trial in Shingles
11/19/2009
More...
|
Mesoblast Limited Sustained Six-Month Improvement In Heart Muscle Function With Revascor, "Off-The-Shelf" Adult Stem Cells
11/18/2009
More...
|
Neovacs SA Release: Preliminary Clinical Results From The Phase I/II Trial Of Tnfa Kinoid In Crohn’s Disease To Be Presented At GASTRO 2009 In London
11/18/2009
More...
|
Galapagos NV (GLPG.BR) Initiates Nanocort(R) Phase II Clinical Trial For Multiple Sclerosis
11/17/2009
More...
|
Addex Pharmaceuticals (ADXN.SW) ADX10059 Monotherapy is Effective on GERD Symptoms in Phase IIb Clinical Trial
11/16/2009
More...
|
Axelar AB Presents the New Anticancer Agent AXL1717 at The AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts, USA
11/13/2009
More...
|
Viron Therapeutics Inc. to Present Data from Phase II Trial at American Heart Association Conference
11/12/2009
More...
|
Tripep: Interim Analysis of ChronSeal(R)
11/12/2009
More...
|
Daval International Limited Awarded Orphan Drug Designation for Motor Neurone Disease Treatment
11/9/2009
More...
|
MorphoSys AG Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 Program
11/9/2009
More...
|
Novexel Starts Phase II Clinical Trial With NXL103 in Adults With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
11/6/2009
More...
|
Breast Cancer Vaccine Tests German Merck KGaA (MKGAF.PK)'s $1 Billion Strategy
11/5/2009
More...
|
European Medicines Evaluation Agency Grants Tikomed Orphan Drug Designation for IBSOLVMIR
11/3/2009
More...
|
Bayer HealthCare Pharmaceuticals (BAY) Presents Florbetaben Phase II Study Results at World Congress of Neurology
10/30/2009
More...
|
ExonHit Therapeutics Inc. Presents New Clinical Advances on Its Alzheimer’s Diagnostic and Therapeutic Programs
10/30/2009
More...
|
Mycenax Biotech Finishes Phase II Trial of Biosimilar Drug
10/28/2009
More...
|
Argos Therapeutics, Inc. Presents Positive Phase 2 Viral Load and Immune Response Data for Arcelis(TM) HIV Program at the AIDS Vaccine 2009 Conference
10/21/2009
More...
|
Bionor Immuno Release: Researchers Find That Vacc-4x Therapeutic Peptide-Based HIV Vaccine Increases CD4 T-Cells in Chronically Infected HIV-1 Patients on Antiretroviral Therapy (ART)
10/21/2009
More...
|
Action Pharma in new Phase II Clinical Trial
10/20/2009
More...
|
Crucell N.V. (CRXL) Rabies Monoclonal Antibody Combination: Positive Results Philippines Phase II Study Presented at RITA Conference
10/20/2009
More...
|
Biogen Idec, Inc. (California) (BIIB) and Biovitrum AB Announce Decision to Advance Long-Acting Hemophilia B Therapy into a Registrational Trial
10/19/2009
More...
|
BioAlliance Pharma Announces Phase I Trial for Fentanyl Lauriad(R) and the Submission of a Clonidine Lauriad(R) Phase II Clinical Trial Application
10/12/2009
More...
|
MediGene AG (DX:MDG) Successfully Completes Patient Recruitment Into Endotag(TM)-1 Phase II Breast Cancer Trial
10/9/2009
More...
|
Immutep S.A. Announces New Interim Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer
10/6/2009
More...
|
Vantia Therapeutics's VA111913 Enters Phase II Proof-of-Concept Trials for Dysmenorrhoea
10/6/2009
More...
|
R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
10/6/2009
More...
|
LifeCycle Pharma Announces Positive Results from a 12 Month Extension Phase of the Phase 2 Clinical Study of LCP-Tacro™ Once Daily in Stable Liver Transplant Patients
9/29/2009
More...
|
Addex Pharmaceuticals (ADXN.SW) Completes Enrollment of First Mid-Stage Clinical GERD Trial
9/28/2009
More...
|
Morphotek Inc.: Farletuzumab Data Presented on Phase II Clinical Trial in First-Relapsed Ovarian Cancer Subjects
9/24/2009
More...
|
Bayer Corporation (BAY) (JOBS), Onyx Pharmaceuticals, Inc. (ONXX)'s Contested Kidney Cancer Drug Shows Benefit
9/23/2009
More...
|
Bayer Corporation (BAY), Onyx Pharmaceuticals, Inc. (ONXX) Pill Beats Hopes in Breast Cancer Test
9/23/2009
More...
|
BioInvent Updates On The Progress Of The Phase II Trial Of The Long Acting Anticoagulant TB-402
9/23/2009
More...
|
MagForce Nanotechnologies Completes Patient Recruitment for Pivotal Glioblastoma Study
9/22/2009
More...
|
Innate Pharma Reports Phase II Clinical Data With Iph 1101 In Oncology
9/21/2009
More...
|
Sosei Group Corporation: QVA149 Phase II Data Presented at the European Respiratory Society Annual Meeting
9/16/2009
More...
|
Cytheris SA Announces Interim Data from INSPIRE Study Showing Interleukin-7 (CYT107) Induces Dose-Dependent and Sustained Increase of CD4 T Cells in Chronic HIV-Infected Patients
9/15/2009
More...
|
AiCuris' Novel HCMV Compound Shows Good Tolerability And Efficacy In Phase II Study
9/15/2009
More...
|
Argenta Discovery Ltd. Publishes Positive Data From a Phase II Proof of Concept Trial with Co-Administration of Inhaled ADC4022 Plus Budesonide Study in COPD
9/15/2009
More...
|
Addex Pharmaceuticals (ADXN.SW)' ADX10059 Has Potential For Parkinson's Disease Levodopa Induced Dyskinesia (PD-LID)
9/14/2009
More...
|
BioLineRx Ltd. Announces Positive Topline Results for BL-1020, a First in Class GABA Enhanced Antipsychotic for the Treatment of Schizophrenia
9/14/2009
More...
|
ExonHit Therapeutics Inc. Presents Promising First Patient Results For EHT 0202, Its Alzheimer's Candidate Drug
9/14/2009
More...
|
Kamada Ltd. Presents Data on Inhaled Alpha-1 Antitrypsin in Cystic Fibrosis Patients at the European Respiratory Society Meeting 2009, Vienna
9/14/2009
More...
|
FDA and European Medicines Evaluation Agency Grant Orphan Drug Designation for ANTISENSE PHARMA GmbH's Investigational Drug Trabedersen in Pancreatic Carcinoma
9/14/2009
More...
|